Gökçe, MustafaVelioğlu, Halil AzizBektay, Muhammed YunusGüler, Eray Metin2023-10-262023-10-262023Gökçe, M., Velioğlu, H. A., Bektay, M. Y. ve Güler, E. M. (2023). Evaluating the clinical significance of diazepam binding inhibitor in alzheimer's disease: A comparison with inflammatory, oxidative, and neurodegenerative biomarkers. Gerontology, 69(9), 1104-1112. https://dx.doi.org/10.1159/0005318490304-324X1423-0003https://dx.doi.org/10.1159/000531849https://hdl.handle.net/20.500.12511/11643Introduction: Alzheimer's disease (AD) is one of the pathologies that the scientific world is still desperate for. The aim of this study was the investigation of diazepam binding inhibitor (DBI) as a prognostic factor for AD prognosis. Methods: A total of 120 participants were divided into 3 groups. Forty new diagnosed Alzheimer patients (NDG) who have been diagnosed but have not started AD treatment, 40 patients who diagnosed 5 years ago (D5YG), and 40 healthy control groups (CG) were included in the study. Levels of DBI, oxidative stress, inflammatory, and neurodegenerative biomarkers were compared between 3 groups. Results: Plasma levels of DBI, oligomeric A?, total tau, glial fibrillary acidic protein, ?-synuclein, interleukin (IL) 1?, IL6, tumor necrosis factor ?, oxidative stress index, high-sensitive C-reactive protein, and DNA damage were found higher in D5YG and NDG as compared to CG (p < 0.001). On the contrary, plasma levels of total thiol, native thiol, vitamin D and vitamin B12 were lower in D5YG and NDG as compared to CG (p < 0.001). Discussion: DBI may be a potential plasma biomarker and promising drug target for AD. It could help physicians make a comprehensive evaluation with cognitive and neurodegenerative tests.enAttribution-NonCommercial 4.0 Internationalinfo:eu-repo/semantics/openAccessDiazepam Binding InhibitorAlzheimer’s DiseaseAgeingBiomarkerInflammationOxidative StressArticle6991104111210.1159/000531849Q30010677613000062-s2.0-8517055512837607528Q1